Precision Medicine Umbrella Trial Expands to Include All NSCLC Patients

Leggi l'articolo originale


The large precision medicine trial known as Lung-MAP has announced it will expand to patients with all non–small-cell lung cancers, accounting for as many as 85% of all lung cancer diagnoses in the US.

Lascia un commento